DIAGNOS Inc. (ADK.V)
| Previous Close | 0.3100 |
| Open | 0.3150 |
| Bid | 0.3050 x 0 |
| Ask | 0.3100 x 0 |
| Day's Range | 0.3000 - 0.3200 |
| 52 Week Range | 0.2300 - 0.5900 |
| Volume | |
| Avg. Volume | 91,550 |
| Market Cap | 22.995M |
| Beta (5Y Monthly) | -0.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | Jul 11, 2024 - Jul 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.00 |
GlobeNewswireDIAGNOS Announces Closing of First Tranche of Private Placement
BROSSARD, Quebec, May 09, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces the closing of a first tranche of 1,125,000 units (each a “Unit”) issued at a price of $0.28 per Unit, for gross proceeds of $315,000, as part of a non-brokered private placement of up to 5,357,142 units, for gross proceeds of up to $1,500,0
- GlobeNewswire
DIAGNOS to Present Cutting-Edge AI Solutions for Retinal Health at ARVO 2024
BROSSARD, Quebec, May 06, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a provider of healthcare services in early detection of certain critical health issues, in collaboration with ETS, École de Technologie Supérieure, is proud to announce its participation in the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting. DIAGNOS will showcase its latest advancements in artificial intelligence applied to retinal imagi
- GlobeNewswire
DIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certification
BROSSARD, Quebec, April 16, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a provider of healthcare services in early detection of certain critical health issues, announces today that it is working on getting new Health Canada and FDA approval on 4 additional AI analysis modules for commercialisation during Q3 2024. These additions to DIAGNOS’ service will provide our customers with a flexible AI-assisted image processing and analysis soluti
